Russian developers focus on new solution to fight viruses and allergies

Print 03 September 2015
MarchMont Innovation News

Nanolek, a Russian biotech firm based in the Kirov region in the Volga area, and the Moscow-based Mechnikov Research Institute of Vaccines and Serums, are pooling efforts in a project aimed at developing and commercializing a new immunobiology drug to fight viral diseases and allergies, the Rusnano website  reported . 

The drug is expected to emerge as a trigger of inborn and adaptive immunity and is therefore considered to be effective against a broad range of pathogens and allergens. When and if developed and brought to market, the solution will be administered to prevent and treat upper respiratory tract infections and chronic upper and lower respiratory tract disorders; allergy-triggered diseases such as bronchial asthma, atopic dermatitis, pollinosis, latex allergy, etc.; herpesvirus infections; papillomavirus infections, chronic urogenital system disorders, including prostatitis; and other diseases. 

It is expected that using this new drug would make it possible to reduce overall therapeutic and antibiotic pressure on the patient’s body. 

According to Dr. V. V. Zverev, a professor and Russian Academy of Medical Sciences member who heads the Mechnikov Research Institute of Vaccines and Serums, research into this next gen immunomodulating solution has taken 15 years to complete. 

Diseases caused by pathogenic microorganisms top all the infectious pathology lists known to physicians and are damaging to economies. A weakening in the human body’s immunological response to intruders, coupled with germs’ ever-growing resistance to antibiotics, can not only increase the severity of a disease but also make it chronic.

Source

Return